The safety and efficacy of teneligliptin 20 mg in Japanese patients with type 2 diabetes has been demonstrated both as monotherapy [15] and in combination with pioglitazone, glimepiride, insulin, and canagliflozin [17–20]. The gene discussed is INS; the disease is type 2 diabetes mellitus.